Related Experiment Videos

ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway

Hsu-Ping Kuo1, Dung-Fang Lee, Chun-Te Chen

  • 11Department of Molecular and Cellular Oncology, Unit 108, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Science Signaling
|February 11, 2010
PubMed

Insights

Arrest-defective protein 1 (ARD1) stabilizes TSC2, inhibiting mTOR activity and tumor growth. This discovery highlights the ARD1-TSC2-mTOR pathway

Area of Science:

  • Cellular Biology
  • Oncology
  • Molecular Mechanisms

Background:

  • The mammalian target of rapamycin (mTOR) pathway is crucial for cellular functions and implicated in tumorigenesis.
  • The tuberous sclerosis 1 (TSC1)-TSC2 complex normally inhibits mTOR activity.
  • Understanding regulators of mTOR is vital for cancer research.

Purpose of the Study:

  • To investigate the role of arrest-defective protein 1 (ARD1) in regulating mTOR signaling.
  • To determine the interaction between ARD1 and the TSC1-TSC2 complex.
  • To assess the impact of ARD1 on tumorigenicity.

Main Methods:

  • Co-immunoprecipitation to confirm physical interaction between ARD1 and TSC2.
  • Western blotting to assess protein acetylation and stability.
  • Cell proliferation assays and autophagy measurements.
  • Analysis of ARD1 and TSC2 expression in tumor samples and cell lines.
  • Evaluation of loss of heterozygosity at Xq28.

Main Results:

  • ARD1 directly interacts with, acetylates, and stabilizes TSC2.
  • ARD1-mediated TSC2 stabilization leads to repression of mTOR activity.
  • Inhibition of mTOR by ARD1 reduces cell proliferation and enhances autophagy.
  • Tumorigenicity is inhibited by ARD1's action on the mTOR pathway.
  • A correlation between ARD1 and TSC2 abundance was observed in various tumor types.
  • Allelic loss of ARD1 at Xq28 was detected in a significant percentage of breast cancer samples.

Conclusions:

  • ARD1 functions as a novel inhibitor of the mTOR pathway.
  • The ARD1-TSC2-mTOR axis represents a potential target for cancer therapy.
  • Dysregulation of the ARD1-TSC2-mTOR pathway may contribute to cancer development.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...